Alembic Pharmaceuticals completes USFDA RRA for its Bioequivalence Facility

Alembic Pharmaceuticals Limited has successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Bioequivalence Facility, Bio-analytical division, located at Vadodara, without any observations. The RRA was conducted from 22nd August, 2022 to 26th August, 2022.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 650.40 as compared to the previous close of Rs. 653.15. The total number of shares traded during the day was 3006 in over 539 trades.

The stock hit an intraday high of Rs. 665.50 and intraday low of 648.30. The net turnover during the day was Rs. 1964821.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 USFDA RemoteRegulatoryAssessment BioequivalenceFacility Vadodara